Non-secretory multiple myeloma: Diagnosis and management

被引:11
作者
Charlinski, Grzegorz [1 ,2 ]
Jurczyszyn, Artur [3 ]
机构
[1] Univ Warmia & Mazury, Dept Internal Med, Olsztyn, Poland
[2] Minist Interior & Adm Hosp, Dept Hematol, Warmian Masurian Canc Ctr, Olsztyn, Poland
[3] Jagiellonian Univ Coll Med, Fac Med, Plasma Cell Dyscrasias Ctr, Dept Hematol, Krakow, Poland
来源
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE | 2022年 / 31卷 / 01期
关键词
diagnosis; management; non-secretory multiple myeloma; IMAGING TECHNIQUES; TRANSPLANTATION; DEXAMETHASONE; LENALIDOMIDE; BORTEZOMIB; CRITERIA; OUTCOMES; DISEASE; CHAIN; AGE;
D O I
10.17219/acem/141455
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Multiple myeloma (MM) is one of the most commonly diagnosed blood cancers. One criterion for the diagnosis of MM is serum and/or urine monoclonal protein produced by clonal plasmocytes. However, about 1-2% of MM cases do not have monoclonal protein. If other diagnostic criteria are present, the possibility of a di-agnosis of non-secretory MM should be considered. As the different types of non-secretory MM depend on the underlying cause, the current definition is considered insufficient. Currently, both the diagnosis and treatment of non-secretory MM are the same as those of secretory MM. Due to the rarity of non-secretory MM, most findings are from retrospective studies on small groups of patients and case reports. The method of monitoring the effectiveness of MM treatment remains a problem, as it is usually based on the assessment of the percentage of clonal plasma cells in the bone marrow and imaging studies.
引用
收藏
页码:95 / 100
页数:6
相关论文
共 50 条
  • [21] Management of multiple myeloma in younger patients
    Strifler, S.
    Einsele, H.
    ONKOLOGE, 2018, 24 (08): : 604 - 608
  • [22] Prognosis of concurrent renal impairment at diagnosis of multiple myeloma: a systematic review
    Zhang, Yanjie
    Pan, Juan
    Kang, Haixin
    Peng, Shuotao
    Tung, Tao-Hsin
    Shen, Bo
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [23] Diagnosis and management of multiple myeloma
    Ely, SA
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (04) : 1194 - 1195
  • [24] Multiple Myeloma: Diagnosis and Treatment
    Michels, Thomas C.
    Petersen, Keith E.
    AMERICAN FAMILY PHYSICIAN, 2017, 95 (06) : 373 - 383
  • [25] Multiple Visceral Resection for Giant Non-Secretory Adrenocortical Carcinoma in an Elderly Patient: A Case Report
    Bacalbasa, Nicolae
    Terzea, Dana
    Jianu, Valeria
    Marcu, Madalina
    Stoica, Claudia
    Balescu, Irina
    ANTICANCER RESEARCH, 2015, 35 (04) : 2169 - 2174
  • [26] Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
    Kothari, Shalin
    Hillengass, Jens
    McCarthy, Philip L.
    Holstein, Sarah A.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (01) : 39 - 46
  • [27] Updates to the guidelines for the diagnosis and management of multiple myeloma
    Pratt, Guy
    Jenner, Matthew
    Owen, Roger
    Snowden, John A.
    Ashcroft, John
    Yong, Kwee
    Feyler, Sylvia
    Morgan, Gareth
    Cavenagh, Jamie
    Cook, Gordon
    Low, Eric
    Stern, Simon
    Behrens, Judith
    Davies, Faith
    Bird, Jennifer
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 167 (01) : 131 - 133
  • [28] Ixazomib in the management of relapsed multiple myeloma
    Touzeau, Cyrille
    Moreau, Philippe
    FUTURE ONCOLOGY, 2018, 14 (20) : 2012 - 2019
  • [29] Non secretory multiple myeloma involving the maxilla: Report of a case with update of biology and new approaches to management
    Gray, ST
    Antunovic, DM
    White, AE
    ORAL ONCOLOGY, 1997, 33 (02): : 136 - 140
  • [30] Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study
    Qin, Xiao-Qi
    An, Gang
    Li, Zeng-Jun
    Liu, Lan-Ting
    Xu, Yan
    Yang, Lin-Hua
    Ma, Yan-Ping
    Deng, Shu-Hui
    Sui, Wei-Wei
    Qin, Yu
    Feng, Xiao-Yan
    Zang, Mei-Rong
    Yang, Wen-Juan
    Zhang, Yan-Ru
    Yi, Shu-Hua
    Wang, Ting-Yu
    Lv, Rui
    Zou, De-Hui
    Zhao, Yao-Zhong
    Qiu, Lu-Gui
    BLOOD ADVANCES, 2019, 3 (05) : 751 - 760